Helix Biopharma Corp Stock Net Income
| HBP Stock | CAD 1.84 0.01 0.54% |
As of the 11th of February 2026, Helix BioPharma retains the Standard Deviation of 4.06, risk adjusted performance of (0.01), and Market Risk Adjusted Performance of 0.0633. Helix BioPharma technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.
Helix BioPharma Total Revenue |
|
| Last Reported | Projected for Next Year | ||
| Net Loss | -6 M | -6.3 M | |
| Net Loss | -10.7 M | -11.2 M | |
| Net Loss | -6 M | -6.3 M | |
| Net Loss | (0.08) | (0.09) | |
| Net Income Per E B T | 0.90 | 0.76 |
Helix | Net Income |
Evaluating Helix BioPharma's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Helix BioPharma Corp's fundamental strength.
Latest Helix BioPharma's Net Income Growth Pattern
Below is the plot of the Net Income of Helix BioPharma Corp over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Helix BioPharma Corp financial statement analysis. It represents the amount of money remaining after all of Helix BioPharma Corp operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Helix BioPharma's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Helix BioPharma's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (5.21 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Helix Net Income Regression Statistics
| Arithmetic Mean | (8,005,576) | |
| Coefficient Of Variation | (39.92) | |
| Mean Deviation | 2,061,458 | |
| Median | (7,911,000) | |
| Standard Deviation | 3,196,014 | |
| Sample Variance | 10.2T | |
| Range | 15.9M | |
| R-Value | 0.35 | |
| Mean Square Error | 9.5T | |
| R-Squared | 0.12 | |
| Significance | 0.16 | |
| Slope | 223,658 | |
| Total Sum of Squares | 163.4T |
Helix Net Income History
Helix Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Helix BioPharma is extremely important. It helps to project a fair market value of Helix Stock properly, considering its historical fundamentals such as Net Income. Since Helix BioPharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Helix BioPharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Helix BioPharma's interrelated accounts and indicators.
Click cells to compare fundamentals
Helix BioPharma 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Helix BioPharma's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Helix BioPharma.
| 11/13/2025 |
| 02/11/2026 |
If you would invest 0.00 in Helix BioPharma on November 13, 2025 and sell it all today you would earn a total of 0.00 from holding Helix BioPharma Corp or generate 0.0% return on investment in Helix BioPharma over 90 days. Helix BioPharma is related to or competes with Satellos Bioscience, Cannara Biotech, HLS Therapeutics, Medicenna Therapeutics Cor, Cardiol Therapeutics, Quipt Home, and Sernova Corp. Helix BioPharma Corp., an immune-oncology company, focuses on the development of cancer drugs in Canada More
Helix BioPharma Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Helix BioPharma's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Helix BioPharma Corp upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.04) | |||
| Maximum Drawdown | 25.72 | |||
| Value At Risk | (6.90) | |||
| Potential Upside | 5.05 |
Helix BioPharma Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Helix BioPharma's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Helix BioPharma's standard deviation. In reality, there are many statistical measures that can use Helix BioPharma historical prices to predict the future Helix BioPharma's volatility.| Risk Adjusted Performance | (0.01) | |||
| Jensen Alpha | 0.0424 | |||
| Total Risk Alpha | (0.50) | |||
| Treynor Ratio | 0.0533 |
Helix BioPharma February 11, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.01) | |||
| Market Risk Adjusted Performance | 0.0633 | |||
| Mean Deviation | 2.68 | |||
| Coefficient Of Variation | (6,067) | |||
| Standard Deviation | 4.06 | |||
| Variance | 16.51 | |||
| Information Ratio | (0.04) | |||
| Jensen Alpha | 0.0424 | |||
| Total Risk Alpha | (0.50) | |||
| Treynor Ratio | 0.0533 | |||
| Maximum Drawdown | 25.72 | |||
| Value At Risk | (6.90) | |||
| Potential Upside | 5.05 | |||
| Skewness | (0.06) | |||
| Kurtosis | 3.26 |
Helix BioPharma Corp Backtested Returns
Helix BioPharma Corp holds Efficiency (Sharpe) Ratio of -0.0554, which attests that the entity had a -0.0554 % return per unit of risk over the last 3 months. Helix BioPharma Corp exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check out Helix BioPharma's Market Risk Adjusted Performance of 0.0633, risk adjusted performance of (0.01), and Standard Deviation of 4.06 to validate the risk estimate we provide. The company retains a Market Volatility (i.e., Beta) of -1.44, which attests to a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Helix BioPharma are expected to decrease by larger amounts. On the other hand, during market turmoil, Helix BioPharma is expected to outperform it. At this point, Helix BioPharma Corp has a negative expected return of -0.23%. Please make sure to check out Helix BioPharma's value at risk, as well as the relationship between the accumulation distribution and day typical price , to decide if Helix BioPharma Corp performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.18 |
Very weak predictability
Helix BioPharma Corp has very weak predictability. Overlapping area represents the amount of predictability between Helix BioPharma time series from 13th of November 2025 to 28th of December 2025 and 28th of December 2025 to 11th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Helix BioPharma Corp price movement. The serial correlation of 0.18 indicates that over 18.0% of current Helix BioPharma price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.18 | |
| Spearman Rank Test | 0.16 | |
| Residual Average | 0.0 | |
| Price Variance | 0.04 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Helix Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Helix BioPharma Corp reported net income of (5.21 Million). This is 101.53% lower than that of the Biotechnology sector and 107.43% lower than that of the Health Care industry. The net income for all Canada stocks is 100.91% higher than that of the company.
Helix Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Helix BioPharma's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Helix BioPharma could also be used in its relative valuation, which is a method of valuing Helix BioPharma by comparing valuation metrics of similar companies.Helix BioPharma is currently under evaluation in net income category among its peers.
Helix Fundamentals
| Return On Equity | -0.66 | ||||
| Return On Asset | -0.3 | ||||
| Current Valuation | 141.15 M | ||||
| Shares Outstanding | 76.38 M | ||||
| Shares Owned By Insiders | 28.90 % | ||||
| Number Of Shares Shorted | 682 | ||||
| Price To Earning | (7.09) X | ||||
| Price To Book | 8.79 X | ||||
| EBITDA | (5.21 M) | ||||
| Net Income | (5.21 M) | ||||
| Cash And Equivalents | 938 K | ||||
| Cash Per Share | 0.01 X | ||||
| Total Debt | 335 K | ||||
| Current Ratio | 0.37 X | ||||
| Book Value Per Share | 0.21 X | ||||
| Cash Flow From Operations | (3.83 M) | ||||
| Short Ratio | 0.28 X | ||||
| Earnings Per Share | (0.07) X | ||||
| Target Price | 2.5 | ||||
| Beta | -0.35 | ||||
| Market Capitalization | 140.54 M | ||||
| Total Asset | 18.8 M | ||||
| Retained Earnings | (215.88 M) | ||||
| Working Capital | (123 K) | ||||
| Net Asset | 18.8 M |
About Helix BioPharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Helix BioPharma Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Helix BioPharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Helix BioPharma Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Helix BioPharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Helix BioPharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Helix BioPharma will appreciate offsetting losses from the drop in the long position's value.Moving against Helix Stock
| 0.76 | HD | Home Depot CDR | PairCorr |
| 0.49 | BCE-PT | Bce Inc Pref | PairCorr |
| 0.43 | DNG | Dynacor Gold Mines | PairCorr |
| 0.38 | CRE | Critical Elements | PairCorr |
| 0.35 | HSTR | Heliostar Metals | PairCorr |
The ability to find closely correlated positions to Helix BioPharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Helix BioPharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Helix BioPharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Helix BioPharma Corp to buy it.
The correlation of Helix BioPharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Helix BioPharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Helix BioPharma Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Helix BioPharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Helix Stock
Helix BioPharma financial ratios help investors to determine whether Helix Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Helix with respect to the benefits of owning Helix BioPharma security.